In Vivo Tumor Progression Studies: An Educational Webinar with Bruker and ImanisJune 15, 2017 -
On June 8, Dr. Kah-Whye Peng, COO of Imanis Life Sciences, co-presented a webinar entitled “In Vivo Tumor Progression Imaging Studies” with Dr. Andrew Van Praagh, Bruker Biospin Field Applications Scientist. The webinar covered the benefits of multimodal reporter gene imaging and how it can be used to accelerate and improve preclinical research. Recent studies performed by Bruker have truly showcased the superior data that can be obtained using Imanis’ high-quality reporter gene expressing cell lines and lentiviral vectors. Using Bruker’s In Vivo Extreme II imaging system, which delivers unmatched sensitivity and speed, these already effective reagents are able to showcase their full potential.
Watch the full webinar here, or continue below for a brief summary of its content.
- Green Fluorescent Protein (GFP) is useful for ex vivo studies at high resolution, but due to high background autofluorescence, it is not suitable for in vivo imaging.
- Near-infrared fluorescent protein (iRFP) is suitable for both in vivo and ex vivo imaging, but still suffers from light attenuation, which limits deep tissue imaging.
- Luciferase offers high sensitivity and the ability to perform serial imaging in live animals, but has limited resolution.
- Nuclear reporters, such as NIS, offer high resolution tomographic images, are suitable for deep tissue imaging, and are clinically translatable. Yet, many institutes lack the equipment necessary for nuclear imaging.
Dr. Van Praagh showed some of the recent data that Bruker has generated from proof-of-concept studies using their In Vivo Extreme II and Imanis A549 cells expressing firefly luciferase and iRFP. These data demonstrated that tumors and metastases could be monitored with high resolution and sensitivity by using multimodal imaging. Click here to see more details of these studies.
Both presenters emphasized the importance of using quality reagents and imaging systems to achieve superior results. Dr. Peng explained how Imanis products are made in-house and undergo rigorous testing. Imanis cell lines are generated from ATCC-licensed parental cell lines that have been authenticated by STR profiling, and all cell lines are certified mycoplasma free.